Hormonal
High body mass index (BMI ≥30 kg/m2) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intra-glomerular pressure.
Maintaining a healthy weight is one of the most effective ways to prevent kidney disease. Excess body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. Focus on sustainable lifestyle changes like balanced nutrition and physical activity to lower your BMI, especially if you have central adiposity (large waist circumference), as this directly reduces the risk of developing chronic kidney disease.
A high body mass index (BMI) is one of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a compensatory hyper filtration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intra glomerular pressure can damage the kidneys and raise the risk of developing Chronic Kidney Disease in the long-term.
Why this rating
Based on numerous large population-based studies, meta-analyses, and consistent observational data cited in the review.
Source
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Elena Zakharova · Urology & Nephrology Open Access Journal · 2017
DOI 10.15406/unoaj.2017.04.00127
More from this paper
- Obesity is associated with a significantly increased risk of kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers.Strong
- Obesity increases the risk of nephrolithiasis (kidney stones) through multiple mechanisms including lower urine pH, increased urinary oxalate, uric acid, sodium, and phosphate excretion, and insulin resistance-induced acidic urine.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →